Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content

Journal of Clinical Investigation

Volumn 117, Issue 8, 2007, Pages 2114-2122

  McCarty, Marya F ^a   Somcio, Ray J ^a   Stoeltzing, Oliver ^a   Wey, Jane ^a   Fan, Fan ^a   Liu, Wenbiao ^a   Bucana, Corazon ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TUMOR VASCULARIZATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA, COMPLEMENTARY; GENE EXPRESSION; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PERICYTES; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TRANSFECTION;

EID: 34547662268     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31334     Document Type: Article

References (46)

1. Ellis, L.M. 2003. A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am. Surg. 69:3-10.
2. Jung, Y.D., et al. 2002. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin. Cancer Biol. 12:105-112.
3. von Tell, D., Armulik, A., and Betsholtz, C. 2006. Pericytes and vascular stability. Exp. Cell Res. 312:623-629.
4. Gerhardt, H., and Betsholtz, C. 2003. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 314:15-23.
5. Sims, D.E. 2000. Diversity within pericytes. Clin. Exp. Pharmacol. Physiol. 27:842-846.
6. Reinmuth, N., et al. 2001. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15:1239-1241.
7. Antonelli-Orlidge, A., Saunders, K.B., Smith, S.R., and D'Amore, P.A. 1989. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc. Natl. Acad. Sci. U. S. A. 86:4544-4548.
8. Orlidge, A., and D'Amore, P.A. 1987. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J. Cell Biol. 105:1455-1462.
9. Hammes, H.P., et al. 2002. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 51:3107-3112.
10. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. 1999. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:159-165.
11. Eberhard, A., et al. 2000. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60:1388-1393.
12. Morikawa, S., et al. 2002. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160:985-1000.
13. Darland, D.C., et al. 2003. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev. Biol. 264:275-288.
14. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:1287- 1295. doi:10.1172/JCI200317929.
15. Gee, M.S., et al. 2003. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am. J. Pathol. 162:183-193.
16. Shaheen, R.M., et al. 2001. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 61:1464-1468.
17. Allt, G., and Lawrenson, J.G. 2001. Pericytes: cell biology and pathology. Cells Tissues Organs. 169:1-11.
18. Betsholtz, C., Karlsson, L., and Lindahl, P. 2001. Developmental roles of platelet-derived growth factors. Bioessays. 23:494-507.
19. Lindahl, P., Johansson, B.R., Leveen, P., and Betsholtz, C. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277:242-245.
20. Soriano, P. 1994. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev. 8:1888-1896.
21. Kitadai, Y., et al. 2006. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int. J. Cancer. 119:2567-2574.
22. Stoeltzing, O., et al. 2003. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res. 63:3370-3377.
23. D'Amore, P.A., and Sweet, E. 1987. Effects of hyperoxia on microvascular cells in vitro. In Vitro Cell Dev. Biol. 23:123-128.
24. Hirschi, K.K., Rohovsky, S.A., Beck, L.H., Smith, S.R., and D'Amore, P.A. 1999. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. Circ. Res. 84:298-305.
25. Josephs, S.F., et al. 1984. Transforming potential of human c-sis nucleotide sequences encoding platelet-derived growth factor. Science. 225:636-639.
26. Clarke, M.F., et al. 1984. Transformation of NIH 3T3 cells by a human c-sis cDNA clone. Nature. 308:464-467.
27. Potapova, O., Fakhrai, H., Baird, S., and Mercola, D. 1996. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Cancer Res. 56:280-286.
28. Westermark, B., Heldin, C.H., and Nister, M. 1995. Platelet-derived growth factor in human glioma. Glia. 15:257-263.
29. Golub, T.R., Barker, G.F., Lovett, M., and Gilliland, D.G. 1994. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:307-316.
30. Tsai, L.H., et al. 1994. Expression of platelet-derived growth factor and its receptors by two pre-B acute lymphocytic leukemia cell lines. Blood. 83:51-55.
31. Westermark, B., et al. 1986. Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc. Natl. Acad. Sci. U. S. A. 83:7197-7200.
32. Klominek, J., Baskin, B., and Hauzenberger, D. 1998. Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin. Exp. Metastasis. 16:529-539.
33. Graves, D.T., et al. 1984. Detection of c-sis transcripts and synthesis of PDGF-like proteins by human osteosarcoma cells. Science. 226:972-974.
34. Betsholtz, C., Westermark, B., Ek, B., and Heldin, C.H. 1984. Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: implications for autocrine receptor activation. Cell. 39:447-457.
35. Yi, B., Williams, P.J., Niewolna, M., Wang, Y., and Yoneda, T. 2002. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 62:917-923.
36. Kawai, T., Hiroi, S., and Torikata, C. 1997. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab. Invest. 77:431-436.
37. Ito, M., et al. 1990. Expression of several growth factors and their receptor genes in human colon carcinomas. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 59:173-178.
38. Anzano, M.A., Rieman, D., Prichett, W., Bowen-Pope, D.F., and Greig, R. 1989. Growth factor production by human colon carcinoma cell lines. Cancer Res. 49:2898-2904.
39. Lindmark, G., et al. 1993. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab. Invest. 69:682-689.
40. Ebert, M., et al. 1995. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int. J. Cancer. 62:529-535.
41. Hwang, R.F., et al. 2003. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin. Cancer Res. 9:6534-6544.
42. Guo, P., et al. 2003. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162:1083-1093.
43. Abramsson, A., Lindblom, P., and Betsholtz, C. 2003. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 112:1142-1151. doi:10.1172/JCI200318549.
44. Darland, D.C., and D'Amore, P.A. 2001. TGF beta is required for the formation of capillary-like structures in three-dimensional cocultures of 10T1/2 and endothelial cells. Angiogenesis. 4:11-20.
45. McGary, E.C., et al. 2002. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin. Cancer Res. 8:3584-3591.
46. Camp, E.R., et al. 2006. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin. Cancer Res. 12:2628-2633.